NEW YORK (TheStreet) -- Agios Pharmaceuticals (AGIO) - Get Report may have one of the first big breaks in cancer treatment that doesn't involve chemotherapy, according to TheStreet's Jim Cramer. 

On CNBC's "Cramer's Stop Trading" segment, the co-manager of the Action Alerts PLUS portfolio said November seems too early for the company to reveal its results for Phase 1 testing of the drug, AG-120.

It seems too early, unless of course, the company has something that is going to be monumental in the future, Cramer added. 

He noted that Celgene (CELG) - Get Report has the marketing rights to the drug and also a large stake in Agios Pharmaceuticals.


-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.